Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06706284 — Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
· Phase 4
· recruiting
NCT05646199 — Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)
· Phase 2, PHASE3
· not yet recruiting
NCT06500429 — A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) A
· Phase 2
· completed
NCT06423599 — Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure
· Phase 2, PHASE3
· recruiting
NCT05895643 — Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?
· Phase 2
· completed
Other recruiting trials for Aging
Currently open trials in the same condition.
NCT02831335 — Technical Development of Multi-Parametric Renocerebral MRI
· recruiting
NCT07099053 — Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging
· recruiting
NCT07504068 — Effects of Physical Exercise and a Nutritional Supplement on Body Composition, Metabolic Function, and Overall Health in
· NA
· recruiting
NCT07525453 — Effects of Three Different Exercise Programs on Dynamic Balance in Community-Dwelling Older Adults
· NA
· recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS
· NA
· recruiting
Other The University of Texas Health Science Center at San Antonio trials
Trials by the same sponsor.
NCT07280897 — SCIPI Implementation and Evaluation: A Multi-site Proof-of-Concept Pilot Trial
· NA
· not yet recruiting
NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D
· Phase 1
· recruiting
NCT07056699 — SGLT2i, Pioglitazone, and Ketone Production in T1D
· Phase 3
· not yet recruiting
NCT06609343 — Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis
· Phase 1, PHASE2
· not yet recruiting
NCT07437053 — Sarcopenia in Chronic Kidney Disease (CKD) Patients
· EARLY_PHASE1
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas Health Science Center at San Antonio
Last refreshed: 4 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05786521.